European Journal of Nutrition

, Volume 55, Issue 1, pp 361–371 | Cite as

Influence of diet supplementation with green tea extract on drug-metabolizing enzymes in a mouse model of monosodium glutamate-induced obesity

  • Iva Boušová
  • Petra Matoušková
  • Hana Bártíková
  • Barbora Szotáková
  • Veronika Hanušová
  • Veronika Tománková
  • Eva Anzenbacherová
  • Barbora Lišková
  • Pavel Anzenbacher
  • Lenka Skálová
Original Contribution

Abstract

Purpose

Consumption of dietary supplements with green tea extract (GTE) is popular for weight management, but it may be accompanied by various side effects, including interactions with drugs. The aim of the present in vivo study was to evaluate the effect of defined GTE (Polyphenon 60) in three dosage schemes on insulin, leptin and drug-metabolizing enzymes in obese mice.

Methods

Experimental obesity was induced by repeated s.c. application of monosodium glutamate to newborn mice. Green tea extract was administered in three dosage schemes in chow diet. The plasmatic levels of insulin and leptin were assayed using enzyme-linked immunosorbent assay. Enzyme activities and mRNA expressions of drug-metabolizing enzymes (totally 13) were analyzed in liver and small intestine using spectrophotometric and HPLC assays and RT-PCR, respectively.

Results

GTE-treatment decreased insulin and leptin levels. Eleven enzymes were significantly affected by GTE-treatment. Long-term administration of 0.01 % GTE caused increase in the activity and mRNA level of cytochrome P450 3A4 (CYP3A4) ortholog in the liver as well as in the small intestine. Interestingly, short-term overdose by GTE (0.1 %) had more pronounced effects on enzyme activities and mRNA expressions than long-term overdose.

Conclusions

GTE-mediated induction of CYP3A4 ortholog, the main drug-metabolizing enzyme, could result in decreased efficacy of simultaneously or subsequently administered drug in obese individuals.

Keywords

Green tea extract Catechins Drug-metabolizing enzymes Obesity Metabolic syndrome 

References

  1. 1.
    Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong WI, Batkai S, Marsicano G, Lutz B, Buettner C, Kunos G (2008) Hepatic CB(1) receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 118:3160–3169. doi:10.1172/Jci34827 CrossRefGoogle Scholar
  2. 2.
    Picklo M, Claycombe KJ, Meydani M (2012) Adipose dysfunction, interaction of reactive oxygen species, and inflammation. Adv Nutr 3:734–735. doi:10.3945/an.112.002626 CrossRefGoogle Scholar
  3. 3.
    Lutz TA, Woods SC (2012) Overview of animal models of obesity. Curr Protoc Pharmacol 58:5.6.1–5.6.18. doi:10.1002/0471141755.ph0561s58
  4. 4.
    Buettner R, Scholmerich J, Bollheimer LC (2007) High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity 15:798–808. doi:10.1038/oby.2007.608 CrossRefGoogle Scholar
  5. 5.
    Olney JW (1969) Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 164:719–721. doi:10.1126/science.164.3880.719 CrossRefGoogle Scholar
  6. 6.
    Matyskova R, Maletinska L, Maixnerova J, Pirnik Z, Kiss A, Zelezna B (2008) Comparison of the obesity phenotypes related to monosodium glutamate effect on arcuate nucleus and/or the high fat diet feeding in C57BL/6 and NMRI mice. Physiol Res 57:727–734Google Scholar
  7. 7.
    Nagata M, Suzuki W, Iizuka S, Tabuchi M, Maruyama H, Takeda S, Aburada M, Miyamoto K (2006) Type 2 diabetes mellitus in obese mouse model induced by monosodium glutamate. Exp Anim 55:109–115CrossRefGoogle Scholar
  8. 8.
    Sasaki Y, Suzuki W, Shimada T, Iizuka S, Nakamura S, Nagata M, Fujimoto M, Tsuneyama K, Hokao R, Miyamoto K, Aburada M (2009) Dose dependent development of diabetes mellitus and non-alcoholic steatohepatitis in monosodium glutamate-induced obese mice. Life Sci 85:490–498. doi:10.1016/j.lfs.2009.07.017 CrossRefGoogle Scholar
  9. 9.
    Fujimoto M, Tsuneyama K, Nakanishi Y, Salunga TL, Nomoto K, Sasaki Y, Iizuka S, Nagata M, Suzuki W, Shimada T, Aburada M, Shimada Y, Gershwin ME, Selmi C (2014) A dietary restriction influences the progression but not the initiation of MSG-Induced nonalcoholic steatohepatitis. J Med Food 17:374–383. doi:10.1089/jmf.2012.0029 CrossRefGoogle Scholar
  10. 10.
    Tsuneyama K, Nishida T, Baba H, Taira S, Fujimoto M, Nomoto K, Hayashi S, Miwa S, Nakajima T, Sutoh M, Oda E, Hokao R, Imura J (2014) Neonatal monosodium glutamate treatment causes obesity, diabetes, and macrovesicular steatohepatitis with liver nodules in DIAR mice. J Gastroenterol Hepatol 29:1736–1743. doi:10.1111/jgh.12610 CrossRefGoogle Scholar
  11. 11.
    Sasaki Y, Shimada T, Iizuka S, Suzuki W, Makihara H, Teraoka R, Tsuneyama K, Hokao R, Aburada M (2011) Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome. Eur J Pharmacol 662:1–8. doi:10.1016/j.ejphar.2011.04.051 CrossRefGoogle Scholar
  12. 12.
    Alarcon-Aguilar FJ, Zamilpa A, Perez-Garcia MD, Almanza-Perez JC, Romero-Nunez E, Campos-Sepulveda EA, Vazquez-Carrillo LI, Roman-Ramos R (2007) Effect of Hibiscus sabdariffa on obesity in MSG mice. J Ethnopharmacol 114:66–71. doi:10.1016/j.jep.2007.07.020 CrossRefGoogle Scholar
  13. 13.
    Fujimoto M, Tsuneyama K, Chen SY, Nishida T, Chen JL, Chen YC, Fujimoto T, Imura J, Shimada Y (2012) Study of the effects of monacolin k and other constituents of red yeast rice on obesity, insulin-resistance, hyperlipidemia, and nonalcoholic steatohepatitis using a mouse model of metabolic syndrome. Evid Based Complement Altern Med 2012:892697. doi:10.1155/2012/892697 CrossRefGoogle Scholar
  14. 14.
    Fujimoto M, Tsuneyama K, Fujimoto T, Selmi C, Gershwin ME, Shimada Y (2012) Spirulina improves non-alcoholic steatohepatitis, visceral fat macrophage aggregation, and serum leptin in a mouse model of metabolic syndrome. Dig Liver Dis 44:767–774. doi:10.1016/j.dld.2012.02.002 CrossRefGoogle Scholar
  15. 15.
    Kumar P, Bhandari U (2013) Protective effect of Trigonella foenum-graecum Linn. on monosodium glutamate-induced dyslipidemia and oxidative stress in rats. Indian J Pharmacol 45:136–140. doi:10.4103/0253-7613.108288 CrossRefGoogle Scholar
  16. 16.
    Kaufhold A, Nigam PK, Dhir RN, Shapiro BH (2002) Prevention of latently expressed CYP2C11, CYP3A2, and growth hormone defects in neonatally monosodium glutamate-treated male rats by the N-methyl-D-aspartate receptor antagonist dizocilpine maleate. J Pharmacol Exp Ther 302:490–496. doi:10.1124/jpet.102.034785 CrossRefGoogle Scholar
  17. 17.
    Matouskova P, Bartikova H, Bousova I, Levorova L, Szotakova B, Skalova L (2015) Drug-metabolizing and antioxidant enzymes in monosodium l-glutamate obese mice. Drug Metab Dispos 43:258–265. doi:10.1124/dmd.114.061176 CrossRefGoogle Scholar
  18. 18.
    Jurgens TM, Whelan AM, Killian L, Doucette S, Kirk S, Foy E (2012) Green tea for weight loss and weight maintenance in overweight or obese adults. Cochrane Database Syst Rev 12:CD008650. doi:10.1002/14651858.CD008650.pub2
  19. 19.
    Seeram NP, Henning SM, Niu YT, Lee R, Scheuller HS, Heber D (2006) Catechin and caffeine content of green tea dietary supplements and correlation with antioxidant capacity. J Agr Food Chem 54:1599–1603. doi:10.1021/Jf052857r CrossRefGoogle Scholar
  20. 20.
    Khan N, Mukhtar H (2013) Tea and health: studies in humans. Curr Pharm Des 19:6141–6147. doi:10.2174/1381612811319340008 CrossRefGoogle Scholar
  21. 21.
    Yang CS, Pan E (2012) The effects of green tea polyphenols on drug metabolism. Expert Opin Drug Metab Toxicol 8:677–689. doi:10.1517/17425255.2012.681375 CrossRefGoogle Scholar
  22. 22.
    Matoušková P, Bártiková H, Bousova I, Szotáková B, Martin J, Skorkovská J, Hanušová V, Tománková V, Anzenbacherová E, Lišková B, Anzenbacher P, Skálová L (2014) Effect of defined green tea extract in various dosage schemes on drug-metabolizing enzymes in mice in vivo. J Funct Foods 10:327–335. doi:10.1016/j.jff.2014.06.026 CrossRefGoogle Scholar
  23. 23.
    Suter M, Butler JE, Peterman JH (1989) The Immunochemistry of Sandwich Elisas. 3. The stoichiometry and efficacy of the protein-avidin-biotin capture (Pabc) System. Mol Immunol 26:221–230. doi:10.1016/0161-5890(89)90075-8 CrossRefGoogle Scholar
  24. 24.
    Gillette J (1971) Techniques for studying drug metabolism in vitro. In: La Du BN, Mandel HG, Way E (eds) Fundamentals of drug metabolism and drug disposition, 1st edn. Williams and Wilkins Company, Baltimore, pp 400–418Google Scholar
  25. 25.
    Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76–85. doi:10.1016/0003-2697(85)90442-7 CrossRefGoogle Scholar
  26. 26.
    Chang TK, Waxman DJ (2006) Catalytic assays for human cytochrome P450: an introduction. Methods Mol Biol 320:73–83. doi:10.1385/1-59259-998-2:73 Google Scholar
  27. 27.
    Maté L, Virkel G, Lifschitz A, Ballent M, Lanusse C (2008) Hepatic and extra-hepatic metabolic pathways involved in flubendazole biotransformation in sheep. Biochem Pharmacol 76:773–783. doi:10.1016/j.bcp.2008.07.002 CrossRefGoogle Scholar
  28. 28.
    Palackal NT, Burczynski ME, Harvey RG, Penning TM (2001) The ubiquitous aldehyde reductase (AKR1A1) oxidizes proximate carcinogen trans-dihydrodiols to o-quinones: potential role in polycyclic aromatic hydrocarbon activation. Biochemistry 40:10901–10910. doi:10.1021/bi010872t CrossRefGoogle Scholar
  29. 29.
    Cullen JJ, Hinkhouse MM, Grady M, Gaut AW, Liu J, Zhang YP, Weydert CJ, Domann FE, Oberley LW (2003) Dicumarol inhibition of NADPH:quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism. Cancer Res 63:5513–5520Google Scholar
  30. 30.
    Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, Lewis AD (1996) Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 88:259–269. doi:10.1093/jnci/88.5.259 CrossRefGoogle Scholar
  31. 31.
    Mizuma T, Machida M, Hayashi M, Awazu S (1982) Correlation of drug conjugative metabolism rates between in vivo and in vitro: glucuronidation and sulfation of p-nitrophenol as a model compound in rat. J Pharmacobiodyn 5:811–817CrossRefGoogle Scholar
  32. 32.
    Habig WH, Jakoby WB (1981) Glutathione S-transferases (rat and human). Methods Enzymol 77:218–231. doi:10.1016/S0076-6879(81)77029-0 CrossRefGoogle Scholar
  33. 33.
    Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402–408. doi:10.1006/meth.2001.1262 CrossRefGoogle Scholar
  34. 34.
    Matoušková P, Bártíková H, Boušová I, Hanušová V, Szotáková B, Skálová L (2014) Reference genes for real-time PCR quantification of messenger RNAs and microRNAs in mouse model of obesity. PLoS ONE 9:e86033. doi:10.1371/journal.pone.0086033 CrossRefGoogle Scholar
  35. 35.
    Roe AL, Howard G, Blouin R, Snawder JE (1999) Characterization of cytochrome P450 and glutathione S-transferase activity and expression in male and female ob/ob mice. Int J Obes Relat Metab Disord 23:48–53CrossRefGoogle Scholar
  36. 36.
    Na HK, Surh YJ (2008) Modulation of Nrf2-mediated antioxidant and detoxifying enzyme induction by the green tea polyphenol EGCG. Food Chem Toxicol 46:1271–1278. doi:10.1016/j.fct.2007.10.006 CrossRefGoogle Scholar
  37. 37.
    Boušová I, Hájek J, Dršata J, Skálová L (2012) Naturally occurring flavonoids as inhibitors of purified cytosolic glutathione S-transferase. Xenobiotica 42:872–879. doi:10.3109/00498254.2012.670737 CrossRefGoogle Scholar
  38. 38.
    Renouf M, Marmet C, Guy PA, Beaumont M, Lepage M, Williamson G, Dionisi F (2013) Dose-response plasma appearance of green tea catechins in adults. Mol Nutr Food Res 57:833–839. doi:10.1002/mnfr.201200512 CrossRefGoogle Scholar
  39. 39.
    Messerer M, Johansson SE, Wolk A (2001) Sociodemographic and health behaviour factors among dietary supplement and natural remedy users. Eur J Clin Nutr 55:1104–1110. doi:10.1038/sj.ejcn.1601272 CrossRefGoogle Scholar
  40. 40.
    Dryden GW, Lam A, Beatty K, Qazzaz HH, McClain CJ (2013) A pilot study to evaluate the safety and efficacy of an oral dose of (-)-epigallocatechin-3-gallate-rich polyphenon E in patients with mild to moderate ulcerative colitis. Inflamm Bowel Dis 19:1904–1912. doi:10.1097/MIB.0b013e31828f5198 Google Scholar
  41. 41.
    Spencer JPE, El Mohsen MMA, Rice-Evans C (2004) Cellular uptake and metabolism of flavonoids and their metabolites: implications for their bioactivity. Arch Biochem Biophys 423:148–161. doi:10.1016/j.abb.2003.11.010 CrossRefGoogle Scholar
  42. 42.
    Kao YH, Hiipakka RA, Liao SS (2000) Modulation of endocrine systems and food intake by green tea epigallocatechin gallate. Endocrinology 141:980–987. doi:10.1210/En.141.3.980 Google Scholar
  43. 43.
    Weng Z, Greenhaw J, Salminen WF, Shi Q (2012) Mechanisms for epigallocatechin gallate induced inhibition of drug metabolizing enzymes in rat liver microsomes. Toxicol Lett 214:328–338. doi:10.1016/j.toxlet.2012.09.011 CrossRefGoogle Scholar
  44. 44.
    Nebert DW, Russell DW (2002) Clinical importance of the cytochromes P450. Lancet 360:1155–1162. doi:10.1016/S0140-6736(02)11203-7 CrossRefGoogle Scholar
  45. 45.
    Yamazaki H, Shimada T (1997) Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys 346:161–169. doi:10.1006/abbi.1997.0302 CrossRefGoogle Scholar
  46. 46.
    Cuendet M, Oteham CP, Moon RC, Pezzuto JM (2006) Quinone reductase induction as a biomarker for cancer chemoprevention. J Nat Prod 69:460–463. doi:10.1021/np050362q CrossRefGoogle Scholar
  47. 47.
    Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136:215–233. doi:10.1016/j.cell.2009.01.002 CrossRefGoogle Scholar
  48. 48.
    Milenkovic D, Deval C, Gouranton E, Landrier JF, Scalbert A, Morand C, Mazur A (2012) Modulation of miRNA expression by dietary polyphenols in apoe deficient mice: a new mechanism of the action of polyphenols. PLoS ONE 7:156–167. doi:10.1371/journal.pone.0029837 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Iva Boušová
    • 1
  • Petra Matoušková
    • 1
  • Hana Bártíková
    • 1
  • Barbora Szotáková
    • 1
  • Veronika Hanušová
    • 2
  • Veronika Tománková
    • 3
  • Eva Anzenbacherová
    • 3
  • Barbora Lišková
    • 3
  • Pavel Anzenbacher
    • 3
  • Lenka Skálová
    • 1
  1. 1.Department of Biochemical Sciences, Faculty of PharmacyCharles University in PragueHradec KrálovéCzech Republic
  2. 2.Faculty of Medicine in Hradec KrálovéCharles University in PragueHradec KrálovéCzech Republic
  3. 3.Faculty of Medicine and DentistryPalacký UniversityOlomoucCzech Republic

Personalised recommendations